公开(公告)号：US10086054B2

公开(公告)日：2018-10-02

申请号：US14392341

申请日：2014-06-26

申请人： ACADEMIA SINICA

发明人： Chi-Huey Wong ,  Chung-Yi Wu ,  Hong-Yang Chuang ,  Chien-Tai Ren

IPC分类号： C07H15/04 ,  A61K39/00 ,  A61K39/385 ,  A61K31/7028 ,  C07K14/47 ,  A61K49/00 ,  C07H15/10 ,  C07H15/14

摘要： Described herein are synthetic glycan conjugates, immunogenic compositions thereof, vaccines thereof, and kits thereof. The present invention further provides methods of using the synthetic glycan conjugates, immunogenic compositions, or vaccines thereof to treat and/or prevent and/or diagnose proliferative diseases such as cancer. The provided glycan conjugate comprises a carrier and a glycan moiety of Formula (I-i) or Formula (I-ii): (structurally represented).

公开(公告)号：US10036033B2

公开(公告)日：2018-07-31

申请号：US14828842

申请日：2015-08-18

申请人： Academia Sinica

发明人： Tuan-Hua David Ho ,  Wan-chi Lin ,  Kuan-Ying Huang

IPC分类号： C12N15/87 ,  C12N15/82

CPC分类号： C12N15/8267

摘要： The present invention relates to a method for inhibiting sprouting, particularly pre-harvest sprouting, in plant seeds, by introducing a polynucleotide encoding a FCA protein into the plant.

公开(公告)号：US10034848B2

公开(公告)日：2018-07-31

申请号：US14925007

申请日：2015-10-28

申请人： Academia Sinica

发明人： Yi-Ping Hsueh

IPC分类号： A61K31/00 ,  A61K31/198

CPC分类号： A61K31/198 ,  A61K31/00

摘要： Disclosed herein is a method for increasing the dendritic spine formation or dendritic spine density in a subject, who is affected by a dendritic spine defect caused by the impairment in neurofibromin (NF1 protein), valosin-containing protein (VCP), atlastin-1 (ATL1), or superoxide dismutase 1 (SOD1). Accordingly, also disclosed herein is a method for treating a subject having or suspected of having a synaptopathy caused by the impairment in NF1, VCP, ATL1, or SOD1.

公开(公告)号：US20180201672A1

公开(公告)日：2018-07-19

申请号：US15322788

申请日：2015-06-30

申请人： Wen-Hwa Lee ,  Academia Sinica

发明人： Wen-Hwa Lee ,  Jin-Yuh Shew ,  Che Ma ,  Chia-Lin Chen ,  Wen-Hsin Lee ,  Chun-Kai Huang ,  Heng-Hsiung Wu

IPC分类号： C07K16/24 ,  A61P35/00 ,  C12N15/113 ,  A61K39/395 ,  A61K45/06 ,  C07K14/715

摘要： Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.

公开(公告)号：US10016748B2

公开(公告)日：2018-07-10

申请号：US14509509

申请日：2014-10-08

申请人： Academia Sinica

发明人： Ming-Hsi Chiang ,  Yu-Chiao Liu ,  Kai-Ti Chu

IPC分类号： B01J31/22 ,  C25B1/02 ,  C07F15/02

CPC分类号： B01J31/226 ,  B01J2231/60 ,  B01J2531/842 ,  C07F15/02 ,  C25B1/02 ,  H01M8/0656

摘要： This invention relates to an iron-sulfur complex that is capable of efficiently catalyzing formation of hydrogen, and a method for producing hydrogen using the complex as a catalyst. The iron-sulfur complex provided herein comprises: a structure of formula (I) wherein the ligands L1 to L3, L5 and L6 and the groups X1 to X3 are each selected from the group consisting of alkyl, alkenyl, alkynyl and aryl that are substituted or unsubstituted, hydroxyl, carbonyl, aldehyde, and so on; L4 is a bridging ligand selected from the group consisting of hydroxyl, carbonyl, and so on; and the symbol “z” means the charge, which is an integer with the range of −3 to +2. X1 and X2 may join together to form a bridging group between the two sulfur atoms. X3 may alternatively be a vacant site.

公开(公告)号：US10005847B2

公开(公告)日：2018-06-26

申请号：US14723181

申请日：2015-05-27

申请人： Academia Sinica

发明人： Chi-Huey Wong ,  Chung-Yi Wu

IPC分类号： C07K16/32 ,  C07K16/40 ,  A61K31/517 ,  A61K39/395 ,  C07K16/28 ,  C12P21/00

CPC分类号： C07K16/40 ,  A61K31/517 ,  A61K39/3955 ,  C07K16/283 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/92 ,  C12P21/005 ,  C12Y302/01 ,  C12Y302/01051

摘要： The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：US09982041B2

公开(公告)日：2018-05-29

申请号：US14599174

申请日：2015-01-16

申请人： Academia Sinica

发明人： Chi-Huey Wong ,  Tsui-Ling Hsu ,  Yi-Wei Lou ,  Chih-Wei Lin ,  Shih-Chi Yeh ,  Chung-Yi Wu ,  Han-Chung Wu

IPC分类号： C07K16/18 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57492 ,  G01N2800/52

摘要： Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：US09976146B2

公开(公告)日：2018-05-22

申请号：US15312667

申请日：2015-05-29

申请人： Academia Sinica

发明人： Chung-Hsuan Chen ,  Bai-Ling Lin ,  Chin-Yu Wang

IPC分类号： C12N15/115 ,  A61K47/48

CPC分类号： C12N15/115 ,  A61K47/55 ,  C12N2310/16 ,  C12N2310/315 ,  C12N2310/3517 ,  C12N2320/13 ,  C12N2320/31 ,  C12N2320/32

摘要： Disclosed herein is an aptamer targeting a MHC-presented peptide and its uses thereof. The MHC-presented peptide is expressed in various cancer cells; therefor, the aptamer of the disclosure is useful as a bio-tool to label and/or treat peptide-presenting cancer cells. Also disclosed herein is a pharmaceutical composition containing the aptamer.

公开(公告)号：US20180112192A1

公开(公告)日：2018-04-26

申请号：US15571249

申请日：2016-05-02

申请人： Andrew Man Chung Wo ,  National Taiwan University ,  Academia Sinica

发明人： Pan-Chyr Yang ,  Pei-Ying Lin ,  Bo-Tsang Huang

IPC分类号： C12N9/12 ,  A61P35/00 ,  A61K38/45 ,  A61K45/06

CPC分类号： C12N9/12 ,  A61K31/517 ,  A61K31/5377 ,  A61K38/179 ,  A61K38/45 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/00 ,  C07K14/71 ,  C07K2319/10 ,  C07K2319/41 ,  C07K2319/43 ,  C12Y207/11001 ,  A61K2300/00

摘要： The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.

公开(公告)号：US20180086801A9

公开(公告)日：2018-03-29

申请号：US15328593

申请日：2015-07-24

申请人： Academia Sinica

发明人： Benjamin Pang-hsien Tu ,  Rita PY Chen ,  Joseph Jen-Tse Huang ,  Yijuang Chern ,  Yu-Song Jang ,  Xiang-Me Lai ,  Tai-Yan Liao ,  Te-Hsien Kung

IPC分类号： C07K14/47

CPC分类号： C07K14/4711 ,  A61K38/00 ,  C07K14/4703 ,  C07K2319/00

摘要： Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.